Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EBT (2019 - 2025)

Historic EBT for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$78.2 million.

  • Nurix Therapeutics' EBT fell 3361.75% to -$78.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$263.7 million, marking a year-over-year decrease of 3641.92%. This contributed to the annual value of -$263.7 million for FY2025, which is 3641.92% down from last year.
  • According to the latest figures from Q4 2025, Nurix Therapeutics' EBT is -$78.2 million, which was down 3361.75% from -$86.4 million recorded in Q3 2025.
  • Over the past 5 years, Nurix Therapeutics' EBT peaked at -$24.2 million during Q1 2021, and registered a low of -$86.4 million during Q3 2025.
  • For the 5-year period, Nurix Therapeutics' EBT averaged around -$44.9 million, with its median value being -$42.6 million (2022).
  • As far as peak fluctuations go, Nurix Therapeutics' EBT plummeted by 10176.06% in 2021, and later skyrocketed by 4652.76% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' EBT stood at -$37.7 million in 2021, then decreased by 24.06% to -$46.7 million in 2022, then increased by 10.19% to -$42.0 million in 2023, then tumbled by 39.53% to -$58.5 million in 2024, then plummeted by 33.62% to -$78.2 million in 2025.
  • Its last three reported values are -$78.2 million in Q4 2025, -$86.4 million for Q3 2025, and -$42.7 million during Q2 2025.